IL130022A0 - Nefazodone dosage form - Google Patents

Nefazodone dosage form

Info

Publication number
IL130022A0
IL130022A0 IL13002299A IL13002299A IL130022A0 IL 130022 A0 IL130022 A0 IL 130022A0 IL 13002299 A IL13002299 A IL 13002299A IL 13002299 A IL13002299 A IL 13002299A IL 130022 A0 IL130022 A0 IL 130022A0
Authority
IL
Israel
Prior art keywords
nefazodone
dosage form
dosage
nefazodone dosage
Prior art date
Application number
IL13002299A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL130022A0 publication Critical patent/IL130022A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13002299A 1998-06-05 1999-05-19 Nefazodone dosage form IL130022A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8821198P 1998-06-05 1998-06-05

Publications (1)

Publication Number Publication Date
IL130022A0 true IL130022A0 (en) 2000-02-29

Family

ID=22210038

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13002299A IL130022A0 (en) 1998-06-05 1999-05-19 Nefazodone dosage form

Country Status (20)

Country Link
US (1) US6143325A (pt)
EP (1) EP0966966A3 (pt)
JP (1) JP2000007567A (pt)
KR (1) KR20000005930A (pt)
CN (1) CN1238181A (pt)
AR (1) AR018862A1 (pt)
AU (1) AU3319999A (pt)
BR (1) BR9901782A (pt)
CA (1) CA2273546A1 (pt)
CO (1) CO5060477A1 (pt)
HU (1) HUP9901830A2 (pt)
ID (1) ID23458A (pt)
IL (1) IL130022A0 (pt)
NO (1) NO992692L (pt)
NZ (1) NZ336001A (pt)
PE (1) PE20000544A1 (pt)
PL (1) PL333524A1 (pt)
SG (1) SG77244A1 (pt)
UY (1) UY25544A1 (pt)
ZA (1) ZA993345B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
EP1428535A1 (en) * 1998-11-02 2004-06-16 ALZA Corporation Controlled delivery of antidepressants
KR20070040421A (ko) * 1998-11-02 2007-04-16 알자 코포레이션 항우울제의 제어된 전달
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
AU2002306616A1 (en) * 2001-03-02 2002-09-19 Sepracor Inc. Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine
BR0205721A (pt) 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
EP1404332A1 (en) 2001-07-06 2004-04-07 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone related applications
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US20050256131A1 (en) * 2002-05-24 2005-11-17 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
ES2336913T3 (es) * 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
EP1732610A2 (en) * 2004-03-26 2006-12-20 Baylor University Targeted serotonin reuptake inhibitors
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
JP2011140510A (ja) * 2011-03-17 2011-07-21 Biovail Lab Inc 塩酸ブプロピオンの放出調節錠剤
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
JP6184903B2 (ja) * 2014-06-04 2017-08-23 ヴァレアント インターナショナル バミューダＶａｌｅａｎｔ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｂｅｒｍｕｄａ 塩酸ブプロピオン放出調節錠剤
JP6078514B2 (ja) * 2014-10-30 2017-02-08 コリア ユナイテッド ファーム，インク 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
ATE236616T1 (de) * 1995-09-29 2003-04-15 Lam Pharmaceutical Corp Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form

Also Published As

Publication number Publication date
BR9901782A (pt) 2000-05-09
PE20000544A1 (es) 2000-06-29
CO5060477A1 (es) 2001-07-30
SG77244A1 (en) 2000-12-19
EP0966966A3 (en) 2000-02-09
AU3319999A (en) 1999-12-16
AR018862A1 (es) 2001-12-12
HUP9901830A2 (hu) 2001-06-28
NO992692D0 (no) 1999-06-03
HU9901830D0 (en) 1999-07-28
ZA993345B (en) 2000-08-22
PL333524A1 (en) 1999-12-06
US6143325A (en) 2000-11-07
UY25544A1 (es) 2001-08-27
NO992692L (no) 1999-12-06
ID23458A (id) 2000-04-27
CN1238181A (zh) 1999-12-15
NZ336001A (en) 2000-09-29
CA2273546A1 (en) 1999-10-10
KR20000005930A (ko) 2000-01-25
JP2000007567A (ja) 2000-01-11
EP0966966A2 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
IL130022A0 (en) Nefazodone dosage form
GB9801363D0 (en) Novel dosage form
HK1033649A1 (en) Extended release dosage form
GB0029386D0 (en) Not known at present
GB9817118D0 (en) Pharmaceutical compounds
GB2357761B (en) Compounds
HUP0203204A3 (en) Oral dosage forms
GB9817623D0 (en) Pharmaceutical compounds
GB0029389D0 (en) Not known at present
GB9810886D0 (en) Pharmaceutical compounds
GB0021654D0 (en) Not available at present
GB9823847D0 (en) Pharmaceutical compounds
GB9823845D0 (en) Pharmaceutical compounds
GB9808665D0 (en) Therapeutic compounds
GB9902399D0 (en) Compounds
GB9824897D0 (en) Therapeutic compounds
GB9817197D0 (en) Pharmaceutical compounds
GB9827865D0 (en) Medicament
GB9808667D0 (en) Therapeutic compounds
GB9821694D0 (en) Amphiphilogel dosage form
ZA989425B (en) Dosage form
GB9828707D0 (en) Pharmaceutical uses
HK1047232A1 (zh) 口服劑型
GB9815388D0 (en) Pharmaceutical compounds
HUP9904478A3 (en) Dosage device